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Abstract
The pilus 2a backbone protein (BP-2a) is one of the most structurally and functionally characterized components of a
potential vaccine formulation against Group B Streptococcus. It is characterized by six main immunologically distinct allelic
variants, each inducing variant-specific protection. To investigate the molecular determinants driving the variant
immunogenic specificity of BP-2a, in terms of single residue contributions, we generated six monoclonal antibodies against
a specific protein variant based on their capability to recognize the polymerized pili structure on the bacterial surface. Three
mAbs were also able to induce complement-dependent opsonophagocytosis killing of live GBS and target the same linear
epitope present in the structurally defined and immunodominant domain D3 of the protein. Molecular docking between
the modelled scFv antibody sequences and the BP-2a crystal structure revealed the potential role at the binding interface of
some non-conserved antigen residues. Mutagenesis analysis confirmed the necessity of a perfect balance between charges,
size and polarity at the binding interface to obtain specific binding of mAbs to the protein antigen for a neutralizing
response.
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Introduction
The bacterial surface is the foremost interface between host and
pathogen, and recognition of the specific epitopes by the immune
system provides the host a key signature to initiate microbial
clearance. Identification and characterization of antigenic epitopes
is a rapidly expanding field of research with potential contributions
to the tailored design of improved, safe and effective vaccines
[1,2]. A number of approaches are currently being used that
require atomic-level information in understanding the rules
governing antibody/antigen interaction, in particular it is the
degree of complementarity between surfaces on epitope and
paratope that determines the affinity and specificity of this
interaction [3–5]. To date, the concept of complementariness is
directly related to the conservation of the amino acid sequence on
a specific neutralizing epitope. A single amino acid change resulted
crucial to alter the surface antigenic properties of a specific epitope
of Neuraminidase (NA) in Influenza virus [6].
Streptococcus agalactiae (also known as Group B Streptococcus or
GBS) is a Gram-positive pathogen causing severe diseases in
newborn and young infants worldwide [7]. Pilin proteins,
structural components of cell surface-exposed appendages, have
been discovered in GBS as important virulence factors as well as
promising vaccine candidates [8]. These high molecular weight
structures are made by a major shaft subunit (named backbone
protein, BP), a major ancillary protein (named AP1), and a minor
ancillary protein (named AP2). BP is distributed regularly along
the pilus structure and is fundamental for pilus assembly whereas
the two ancillary proteins are dispensable [9]. AP1 is thought to be
located at the tip of the assembled pilus structure, while AP2 is
involved in pilus attachment to the cell wall [10–12]. In GBS three
pathogenicity islands, named Pilus Island-1 (PI-1), Pilus Island-2a
(PI-2a) and Pilus Island-2b (PI-2b), each encoding pilin protective
subunits, have been identified [9]. Among them, the backbone
protein of Pilus Island 2a (BP-2a) is a key component of a
promising pilus-based vaccine formulation against Group B
Streptococcus infections [13,14]. However, this protein showed the
highest level of gene variability among all pilin antigens,
characterized by six non cross-protective allelic variants [13].
Each variant identified was able to induce protective immunity in
mouse models and opsonophagocytosis killing of live bacteria, but
only against GBS strains expressing the homologous variant
[13,14]. A recent Structural Vaccinology approach applied to the
BP-2a protein led to the identification of the minimal protein
domain carrying the protective epitopes [14]. By using in vitro
opsonophagocytosis assays and in vivo animal infectious models, we
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demonstrated that, within each variant, the domain D3 is
responsible for eliciting neutralizing antibodies against pathogen
homologous infections [14]. This structure-based approach
combined with immunological assays succeeded in the generation
of an easy-to-produce chimeric antigen capable to elicit protection
against the majority of circulating GBS serotypes [14]. However,
the specific mechanisms by which antibodies raised against each
variant can mediate a neutralizing response only against GBS
strains expressing the homologous variant are not completely
understood.
The aim of this work is to contribute a deeper understanding
of the molecular basis driving the immunogenic specificity of
single BP-2a variants, explaining the mechanism by which
amino acid variability on the antigen surface may allow the
bacteria to adapt to the host environment and/or escape its
immune system. To investigate the variant-specific immunoge-
nicity of BP-2a at the molecular level, we generated neutralizing
monoclonal antibodies (mAbs) raised against a specific allelic
variant of the protein, the 515 allele [13,14]. The produced
mAbs were functionally screened according to their ability to
recognize the polymerized pilus structure on the bacterial
surface and to mediate opsonophagocytosis GBS killing in vitro.
By Surface Plasmon Resonance (SPR) technology we deter-
mined their binding affinity. An approach based on partial
digestion, immunocapture and mass spectrometry was used to
identify the epitope region in the antigen. Finally, docking and
molecular simulation prediction studies were used to elucidate
the intrinsic and functional affinity between mAbs and antigen
at a residue level.
This work describes a potential strategy to investigate the
immunological and structural properties of a surface virulence
factor, by elucidating at the molecular level the chemical-physical
properties directly related to an effective neutralizing response
against pathogen infection.
Results
Generation of mouse monoclonal antibodies targeting
surface-exposed epitopes of the pilin protein BP-2a 515
variant
Recent advances in monoclonal antibodies (mAbs) technology
suggested us to use them as tool to investigate the principles
governing functional antibody/antigen interactions [6]. So, to
understand the immunological differences among the six different
variants of the highly immunogenic GBS protein BP-2a through
the identification of neutralizing epitope(s), mouse monoclonal
antibodies (mAbs) against the 515 allelic variant were generated
following standard procedures (see Materials and Methods). Since
surface accessibility of bacterial proteins is a fundamental pre-
requisite of antibodies for mediating an effective humoral response
against bacterial infections, selection criteria for mAb identifica-
tion were based on variant-specificity and on bacterial surface
staining, which was investigated by Flow Cytometry (FACS)
analysis. The screening procedure resulted in the identification of
six different monoclonal antibodies (named 4H11/B7, 17C4/A3,
27F2H2/H9, 14F6/A1, 25B7/D7, 28E7/E4) able to recognize
only the polymeric pilus structure on the bacterial surface of their
homologous strain 515 (Figure 1A). In fact, they were not able to
stain the surface of GBS strains expressing a different BP-2a
variant (Figure 1A).
To assess if the six selected mAbs could also mediate a
functional immunogenic response against GBS we performed an in
vitro opsonophagocytosis assay, using as effector cells differentiated
HL60 cells, as described in the Materials and Methods section,
and GBS strain 515. We analyzed each monoclonal antibody at
three different dilutions in presence of baby rabbit complement. As
shown in Figure 1B, only three out of six mAbs (4H11/B7,
17C4/A3 and 27F2H2/H9) were able to mediate an effective
complement-dependent opsonization and killing of GBS bacteria,
meaning that these mAbs can recognize and bind neutralizing
epitopes exposed in the pilin protein on the bacterial surface.
Biochemical characterization of selected mAbs
Classes and subclasses of the six monoclonal antibodies were
determined as described in the Materials and Methods section.
Clone 4H11/B7 secreted the IgG2b subclass; clone 17C4/A3 and
27F2H2/H9 secreted the IgG2a subclass whereas clones 14F6/
A1, 25B7/D7 and 28E7/E4 had the IgG1 isotype.
To evaluate the interaction between BP-2a 515 variant and the
selected mAbs, we conducted SPR (Surface Plasmon Resonance)
analyses. A convenient strategy to study this interaction is to
capture the antibody on a surface containing Fc-receptors in order
to place the antibody in a well-defined orientation for binding
analysis. Two CM5 biosensors, one coated with Protein A and the
second with Protein G, were prepared in order to steadily capture
the different isotypes of the mAbs and study their interaction with
BP-2a 515 variant in terms of association (ka) and dissociation (kd)
rate constants, and binding affinity (KD= kd/ka).
The monoclonal antibodies 17C4/A3 and 27F2/H2/H9 were
captured on both Protein A and Protein G biosensors while 4H11/
B7 mAb was stably captured only in presence of Protein G. Two
out of the three IgG1 mAbs, 25B7/D7 and 28E7/E4, were
captured by Protein G, increasing the RU (refractive unit) of
capture according to the concentration (5 or 15 nM), while 14F6/
A1 was not captured by protein G up to the concentration of
15 nM. After the capture, the mAbs (4H11/B7, 17C4/A3 and
27F2H2/H9) that were the same antibodies that were able to
mediate opsonophagocytic killing of GBS cells could bind BP-2a
515 variant, while the two IgG1 mAbs captured by the Protein G
Author Summary
Group B Streptococcus (GBS) is the leading cause of
neonatal invasive diseases and pili, as long filamentous
fibers protruding from the bacterial surface, have been
discovered as important virulence factors and potential
vaccine candidates. The bacterial surface is the main
interface between host and pathogen, and the ability of
the host to identify molecular determinants that are
unique to pathogens has a crucial role for microbial
clearance. Here, we describe a strategy to investigate the
immunological and structural proprieties of a protective
pilus protein, by elucidating the molecular mechanisms, in
terms of single residue contributions, by which functional
epitopes guide bacterial clearance. We generated neutral-
izing monoclonal antibodies raised against the protein and
identified the epitope region in the antigen. Then, we
performed computational docking analysis of the antibod-
ies in complex with the target antigen and identified
specific residues on the target protein that mediate
hydrophobic interactions at the binding interface. Our
results suggest that a perfect balance of shape and
charges at the binding interface in antibody/antigen
interactions is crucial for the antibody/antigen complex
in driving a successful neutralizing response. Knowing the
native molecular architecture of protective determinants
might be useful to selectively engineer the antigens for
effective vaccine formulations.
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biosensor did not bind to the protein in the range of 0.5 to 2.5 mM.
For the mAbs which were able to bind the BP-2a 515 variant
single cycle kinetics were performed on both biosensors when
possible. The average of three independent runs is reported in
Table 1. Data showed that the association phase (ka) resulted
comparable for all the tested mAbs, within a range of,2.5-fold (ka
max/ka min). Larger differences were measured in the kinetic of
dissociation kinetics (kd), with the most stable binding observed for
4H11/B7, kd approximately 10-fold slower than for 17C4/A3 and
5.5-fold slower than for 27F2/H2/H9 mAb. Nevertheless, the
corresponding thermodynamic dissociation constants (KD) did not
differ among the three mAbs, which showed to strongly bind the
BP-2a 515 variant.
Mapping with functional mAbs identifies an epitope in
domain D3
To identify the neutralizing epitope on BP-2a 515 variant,
an epitope mapping with the three functionally active
monoclonal antibodies (27F2/H2/H9, 17C4/A3 and 4H11/
B7) was performed. Two different MS-based approaches were
used, one of them allowing the identification of conformational
epitopes (see Materials and Methods). With either approach,
the experiments were performed six times, using the proteases
trypsin, LysC and GluC, and using the mutant form of the
entire protein lacking the three isopeptide bonds (BP-2a-
515K199A/K355A/K463A) previously generated [14]. It is well-
known that the presence of internal isopeptide bonds is
important for the stability and resistance to proteolysis of
single structurally independent domains in which the protein is
organized. The results indicate that the three monoclonal
antibodies recognize the same region of BP-2a-515 in domain
D3, with sequence 411-TYRVIERVSGYAPEYVSFVNGVV-
TIK-436. The domain D3 was the same protein portion
previously characterized as the domain carrying most of the
epitopes inducing protective antibody responses [14].
Figure 2A shows the mass spectrum of the total LysC
digestion of BP-2a-515 (upper panel) and that of the peptides
immunocaptured with 4H11/B7 (lower panel). The two
labeled signals in the lower panel correspond to the fragments
of BP-2a-515 sharing the 411–436 sequence (Figure 2B). To
confirm the sequence of these peptides, MS/MS spectra were
obtained for the peak with a m/z = 2946.530 Da. For the peak
with a m/z = 4156.461Da no MS/MS was recorded due to the
low intensity of the signal. When using trypsin and GluC no
immunocaptured peptide fraction could be detected. Since the
peptides retained by the antibodies after LysC digestion
contained R and E residues, potential cleavage sites for trypsin
and GluC, respectively, these results suggest that the residues
R and E and their immediate neighbors may play a role either
in the interaction with mAbs or in the structural arrangement
of the epitope, since cleavage at either site prevents binding. In
the BP-2a-515 structure (PDB code: 2XTL) [14] it can be
observed that the residues that are exposed at the surface are
comprised between Glu424 and Lys 436 (Figure 2C). The fact
that the two approaches tested (see Materials and Methods)
lead to the same result indicates that epitope recognition is
primarily based on sequence.
Figure 1. Selected mAbs against BP-2a 515 variant recognize only the polymerized pilus structures of the homologous strain and
can mediate complement-dependent bacterial clearance. (A) Flow cytometry analysis on whole GBS strains stained with mAbs raised against
BP-2a 515 variant. Six GBS strains expressing different BP-2a variants were used in the assay, strain CJB111 (cjb111 allele); strain H36B (h36b allele);
strain CDC84 (dk21 allele); strain CDC89 (cjb110 allele); strain 3050 (2603 allele) and strain 515 (515 allele). Fixed bacteria were stained with
monoclonal antibodies and then labeled with R-Phycoerythrin conjugated goat anti-mouse secondary antibodies. Black filled histograms indicate
staining of bacteria with only secondary antibody. (B) Opsonophagocytosis activity of the selected six monoclonal antibodies. 104 CFUs of GBS strain
515 were incubated for 1 h with differentiated HL60 cells, baby rabbit complement and monoclonal antibody (1:30, 1:90, and 1:270 dilutions). The
log10 differences between GBS colony-forming units at time 0 (10
4 CFU) and time 1 h are shown. The mAbs used are recorded above each bar. Black
shaded bars represent negative control (without baby rabbit complement); grey bars correspond to the polyclonal serum specific for the full length
BP-2a 515 protein, used as positive control. Error bars indicate standard deviation from two independent experiments.
doi:10.1371/journal.pcbi.1003115.g001
Table 1. Kinetic analyses of 17C4/A3, 27F2/H2/H9 and 4H11/
B7 mAbs interacting with BP-2a 515 variant.
mAb ka (1/Ms) kd (1/s) KD (nM)
17C4/A3 9.663.3 E+04 9.263.3 E-04 9.661.1
27F2H2/H9 8.663.0 E+04 4.761.3 E-04 5.761.3
4H11/B7 3.960.2 E+04 8.560.7 E-05 2.260.1
The association (ka) and dissociation (kd) rate constants, and the binding affinity
(KD) are the average of three independent runs for each monoclonal antibody.
For mAb 25B7/D7, 28E7/E4 and 14F6/A1 (15 nM), it was not possible to
determine the kinetic parameters since the first two did not binding to GBS 59
(0.5–2.5 mM) while the third could not be captured on Protein G biosensor.
doi:10.1371/journal.pcbi.1003115.t001
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Functional mAbs bind BP-2a 515 on the same region of
D3 domain, centered on the same key residues: VAL429
and ASN430
To investigate the mode of action of neutralizing mAbs on the
antigen BP-2a 515, we performed mAbs-protein docking. Mono-
clonal antibodies sequences were obtained by isolation of total
RNA from each hybridoma cell line and reverse-transcription.
Then, using the generated cDNA as template, the heavy (VH) and
light (VL) chains were amplified using specific PCR primers.
Sequence comparison of the three neutralizing mAbs is showed in
Figure 3 and all light chains were of the k-type.
To elucidate the residue-specific interaction between antigen
and antibody at the binding interface, after mAbs sequencing, a
structural model of the Fv domain of two of them (17C4/A3 and
4H11/B7) was developed using Modeler 9v8 [15]. Template
crystal structures for mAb 17C4/A3 were selected from PDB
showing 80% sequence identity for an antibody variable heavy
chain (PDB entry 1H3P) and 79% sequence identity for an
antibody variable light chain (PDB entry 2ROW). The same
procedure led to the selection of two template crystal structures for
mAb 4H11/B7 sharing 90% sequence identity for the light chain
(PDB entry 1I9J) and 76% sequence identity for the heavy chain
(PDB entry 3O6M). In both cases, light and heavy chains were
packed together and energy minimized before proceeding with
docking studies.
To investigate at the amino-acid level the molecular interactions
between neutralizing mAbs and BP-2a antigen, the modeled
structures of antibodies were docked against the partial crystal
structure of the antigen [14] using ATTRACT [16]. Knowing that
mAbs bind to the D3 domain of the antigen in the region T411-
K436, we used this information to screen the most accurate
complexes within a range of 15000–20000 complexes generated
by the docking program.
To validate the stability and reliability of the best selected
complexes, we performed explicit solvent molecular dynamics
simulation using GROMACS 4.0.5 simulation package [17].
Figure 2. Mapping with functional mAbs identifies an epitope in domain D3. (A) Mass spectrum obtained for the LysC digestion of BP-2a
(upper panel) and peptides immunocaptured by mAb 4H11/B7 (lower panel). (B) Sequences corresponding to the immunocaptured peptides
(2946.530 Da and 4156.461 Da). (C) Detail of the identified epitope in the structure; in yellow the identified peptide and in red the surface
representation of the identified peptide. Note that the segment Glu424 to Lys436 is the most accessible one.
doi:10.1371/journal.pcbi.1003115.g002
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Molecular dynamics results of best docked solutions of mAbs/
BP-2a antigen revealed different binding orientations of the
neutralizing mAbs against the target protein which showed the
importance of specific residues both in the epitope and in the
paratope. Molecular simulation results indicated that a shorter
portion of the previous identified epitope might be necessary at
binding interface: P423-K436 in 17C4/A3-complex (Figure 4A)
and V426-K436 in 4H11/B7-complex (Figure 4B). In particular,
during the course of the simulation, the distance between those
residues and the CDR remained at a contact distance of around 4
Angstrom, indicating their importance for complex interaction
and stability. Although two different mAb binding orientations
were identified as sterically possible, two amino acid residues
located on the target antigen were identified as fundamental at the
binding interface in both cases: Val429 and Asn430. Remarkably,
residue 429 had been identified as being under selective pressure,
which is consistent with a direct role in the interaction with the
antibody. Both mAb binding interfaces form a deep cleft filled by a
loop region of domain D3. In the docking models residues Val429
and Asn430 fill the deeper cavity of both clefts in a water-free
environment (Figure 5). Val429 is involved in hydrophobic
interaction with Val206, Arg208 and Ser204 in the 17C4A3-
antigen complex (Figure 6A), whereas it interacts with Val207,
Leu317, Asn320 and Tyr321 in the 4H11/B7-antigen complex
(Figure 6B). Asn430 is predicted to interact with residue Glu269
and Arg208 through H-bonds and makes polar interactions with
Ala252, Ser254 and Ile318 in the 17C4A3-complex (Figure 6A),
while it establishes through polar interactions with Tyr321 and
Tyr277 residue in the 4H11/B7-complex (Figure 6B).
The epitope is subject to sequence variation and
selective pressure
The level of conservation of the epitope was analyzed in a set of
144 BP-2a sequences from different GBS isolates. An alignment of
the protein sequences revealed six main variants, as described in
previous work [13]. In the full protein alignment, inter-variant
variability is high (p distance = 0.31) with relatively few conserved
positions (25%), while intra-variant variability is low, suggesting a
mosaic structure (see full alignment in Supplementary Material).
Comparative sequence analysis of the identified epitope region
among the BP-2a protein sequences divided the isolates into the
same variants (Figure 7A) with the same variability pattern of the
full protein (p distance = 0.37 and 26% conserved sites). The
alignment also showed that the epitope region has a more
conserved first half, residues 411 to 423 (sequence 515), and a
more divergent second half, residues 424 to 436 (Figure 7B). In
addition, the unique BP-2a nucleotide sequences were aligned to
study the genetic events causing the observed variability. A
recombination analysis using GARD [18] identified two statisti-
cally significant break points located at codon positions 198 and
636 (sequence 515). To distinguish the effect of mosaicism and
point mutations in epitope variability, results from the GARD
algorithm were taken into account for the estimation of positive
selection. Thus, the REL algorithm implemented in HyPhy [19]
identified 16 sites under selective pressure in BP-2a (Supplemen-
tary Material), one of them (Val429, sequence 515) located in the
epitope region (Figure 7A). These results suggest that both
recombination and selection of advantageous mutations have
acted to generate the six BP-2a variants for both the full protein
and the epitope region. In particular, residue 429 could be
changing in response to the pressure of the immune system and be
thus a key element for immunological specificity.
To further confirm single amino acid contributions to mAb-
epitope binding and elucidate molecular determinants of the
immunological specificity of each BP-2a allelic variant, a peptide
dot blot immunoassay was performed. Combining epitope
mapping, docking and molecular dynamics results with alignment
data and detected signatures of positive selection (Figure 7A), four
mutated peptides were synthesized (Figure 7B) and used to
evaluate the contribution of single point mutations at the mAb-
antigen binding interface. In particular, major consideration was
reserved on those residues found to reach the deeper cavity of the
mAbs cleft: Val429 and Asn430. The designed mutations were
aimed at testing the effect of size and charge of the side chains of
these two residues on the binding to the antibodies. Mutating both
the Asn430 and Val429 to an alanine residue resulted in a
conserved capability of binding to the two mAbs, even with
increased affinity in the case of Val429 substitution. On the other
Figure 3. Protein sequences of the three functionally active mAbs. Sequence comparison between the functionally active mAbs selected
against BP-2a protein 515 variant. CDR1, CDR2, and CDR3 as defined by Kabat et al. [39] are highlighted.
doi:10.1371/journal.pcbi.1003115.g003
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hand, mutating either residue to lysine, that carries a bulkier and
positively charged side chain, substantially reduced or completely
abolished the binding of the mAbs to the spotted peptides
(Figure 7B). The results from lysine substitution support the
presence of residues 429 and 430 at the interaction interface
(highly perturbed by a lysine) while those from alanine substitution
suggest that these two residues are not responsible for specificity
but their nature is probably limited by their fit in the cavity.
Discussion
The ability of the host to identify microbial molecular
determinants that are unique to pathogens has a crucial role in
host defense. The recognition by the immune system of the host of
surface exposed components, such as proteins and polysaccharides
represents the start signal for microbial clearance. Characteriza-
tion studies of vaccine formulations require a deep knowledge of
the interactions between pathogen and host immune system and
vaccine components should include the molecular determinants
able to stimulate an effective immune response against a specific
pathogen. The data reported in this work show a significant
correlation between the molecular interactions of monoclonal
antibody/target protein with successful neutralizing response
against bacterial infection.
The protection against GBS has been associated with the
production of high levels of neutralizing antibodies which
specifically recognize the antigens exposed on bacterial surface
[20,21]. However, the specific mechanisms, in terms of single
molecular determinants, by which antibodies neutralize GBS
infections, are not completely understood. Moreover, it is well-
known that GBS as well as many other bacteria have evolved a
wide range of mechanisms to escape the immune system of their
hosts or to adapt to environmental variation, for instance,
adopting the strategy of gene variability and/or differential gene
expression. These strategies play a crucial role in the capacity of
pathogens to trigger disease and also explain why it is so difficult to
develop vaccines against these microorganisms. Thus, positive
selection and recombination have played an important role in
adaptation of the core-genome of different Streptococcus species to
different hosts [22]. In this context, the identification of different
allelic variants of a key vaccine candidate, such as the pilin protein
BP-2a, able to induce variant-specific protection [13] clearly
reflects a typical strategy of the bacterium to escape the immune
system of the host and, at the same time, represent an additional
confirmation of the important role of this protein in GBS
virulence. Recent data showed that the majority of protective
epitopes of the different BP-2a alleles are located in a single
structurally independent domain, called D3 domain [14]. A
synthetic chimeric protein constituted by the protective D3
domain of the six BP-2a variants was able to protect mice against
the challenge with all of the type 2a pilus-carrying strains [14]. In
this work we have investigated the contribution of single amino
acid residues within the immunodominant domain D3 of BP-2a,
able to drive the neutralizing host humoral response. As a tool to
investigate the principles governing functional antibody/antigen
interactions at the amino acid level, we successfully selected
functionally active monoclonal antibodies targeting the 515 allelic
variant of the pilin BP-2a. The selected mAbs were able both to
recognize the polymerized pilus structure on bacterial surface and
to mediate complement-dependent opsonophagocitic killing of live
bacteria.
Epitope mapping analysis of two of the neutralizing mAbs
identified showed that the mAbs bind to the same region of BP-2a-
515 in domain D3, the same domain previously identified as the
immunodominat protein region carrying protective epitopes [14].
Figure 4. Molecular mAbs/BP-2a 515 variant docking reveals two different binding orientations. (A) Ribbon representation of mAb
17C4/A3-BP-2a 515 variant complex. (B) Ribbon representation of mAb 4H11/B7-BP-2a 515 variant complex. In both complexes, the binding interface
is CPK represented and colored according to the mAbs and antigen overall structure.
doi:10.1371/journal.pcbi.1003115.g004
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Figure 6. Surface representation of the antibodies binding interface. (A) Deep view of 17C4/A3-peptide complex. Antibody interface is
orange colored and the peptide is represented as dark grey stick. (B) Deep view of 4H11/B7-peptide complex. Antibody interface is green colored and
the peptide is represented as dark grey stick. In both panels, the fundamental residues for binding interaction are indicated.
doi:10.1371/journal.pcbi.1003115.g006
Figure 5. Identification of surface residues that mediate the interaction. (A) Side and (B) front view of mAb 17C4/binding site. (C) Side and
(D) front view of mAb 4H11/B7 binding site. In all the panels, the model structure of mAbs is represented as surface, colored by interpolated charge.
MAbs are shown in complex with the identified immunogenic peptide (stick) located into the D3 domain of the protein. The residues of the protein
antigen, Val429 and Asn430, are represented as green stick and colored surface.
doi:10.1371/journal.pcbi.1003115.g005
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Although these results confirmed the importance of D3 domain for
immunogenicity and protection capacity of BP-2a, to elucidate the
specific affinity of the antibodies versus their protein target a
structural analysis of the mAbs alone and in complex with the
target antigen has been performed. Molecular docking and MD
simulation studies indicated that only two specific residues on the
target protein, Val429 and Asn430, were able to reach the deepest
cavity formed by the antibody binding interface, mediating specific
hydrophobic and polar/H-bond interactions, respectively.
Previous studies support the importance of single amino-acid
residues at the binding interface in mAb/antigen interactions,
responding to a strict balance of shape and energetics. In the case
of Influenza virus (H3N2 vaccine strains 1968–2007), modeling
and antigen/antibody docking analyses revealed the molecular
basis of the interactions between Hemagglutinin (HA) protein, the
primary target of the human immune system, and monoclonal
antibodies [6]. Specific mutations both in the neutralizing epitopes
and in their vicinity altered the protein surface and the surface
electrostatics of the virus, leading to the loss of recognition by the
antibody [6]. Though the epitopes responsible for immunity were
very similar in successive variants of HA, the simulations could
explain the antigenic drift of pathogen surface determinants that
has been responsible for the loss of immunity against Influenza
infection even in vaccinated population [6]. It has been also shown
that single-residue mutants of an antigen may prevent docking by
increasing the free energy barrier to conformational rearrange-
ments required for binding to the antibody [23]. In light of this
data, the variability of the epitope region identified in BP-2a has
been analysed, including the detection of events of recombination
and positive selection. Both factors have been found to be
significant players in epitope variability. Thus, recombination is
likely to be at the basis of the six allelic variants known today and,
in addition, residue 429 is predicted to be under positive selection.
Interestingly, this residue is located in a part of the epitope region
that has low conservation, strengthening the hypothesis of a GBS
antigenic drift to escape the immune response and to adapt to the
host.
To further characterize the epitope recognized by 4H11/B7
and 17C4/A3 mAbs, a functional dot blot assay using mutated
peptides was performed. To identify functional residues within the
neutralizing epitope, we mutated those residues predicted to be
fundamental at the binding interface (Val429 and Asn430) to
lysine and alanine. Mutating Val429 and Asn430 into alanine did
not drastically affect mAb surface electrostatics and did not
generate steric interferences that could inhibit the binding of
antibody. This indicates that a perfect surface antigen-antibody
complementarity in this region is not necessary for binding.
Conversely, changing the same residues in lysine resulted in a
decreased, in the case of Val429, and in a complete abolishment,
in the case of Ans430, of mAb binding. The substitution of valine
or asparagine by lysine introduces a drastic perturbation of the
shape and electrostatics of the antigen surface at this region. The
fact that this perturbation inhibits binding supports the presence of
these two residues at the interface.
Overall, this study provides new insights into mAbs-BP-2a 515
variant interactions and highlights the molecular correlation
between BP-2a variability and its immunological specificity.
Moreover, the identification of a neutralizing epitope of a highly
immunogenic antigen could be useful for a knowledge-based
design of effective vaccines, avoiding the side effects of unfavorable
epitope(s) and stringently targeting the immune response only on
those one(s), belonging either to the same or to different antigenic
protein(s), responsible of pathogenic clearance. Knowing the
native molecular architecture of protective determinants could be
possible to selectively engineer the antigens for including them in a
more effective vaccine formulation.
Materials and Methods
Ethics statement
Animal treatments were performed in compliance with the
Italian laws and approved by the institutional review board
(Animal Ethical Committee) of Novartis Vaccines and Diagnostics,
Siena, Italy.
Figure 7. Single amino acid contribution to mAbs-antigen interaction. (A) Sequence alignment of the identified epitope region in the 22 BP-
2a allelic variants. The alignment is colored according to sequence identity from dark blue to white. The neighbor-joining phylogenetic tree has been
constructed with the full 22 BP-2a protein sequences. The epitope alignment clearly illustrates a mosaic structure in the protein indicating the
presence of recombination events. An asterisk indicates a position under positive selection. (B) Peptide dot blot immune assay of wild type and
mutated peptide with 17C4/A3 and 4H11/B7 mAbs. The mutated residues within each synthetized peptide are highlighted in red.
doi:10.1371/journal.pcbi.1003115.g007
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Bacterial strains, media, and growth conditions
GBS strains used in this work are 515 (serotype Ia, expressing
BP-2a-515 allele); CJB111 (serotype V, expressing BP-2a-CJB111);
H36B (serotype II, expressing BP-2a-H36B); 3050 (type II,
expressing BP-2a-2603); CDC84 (serotype II, expressing BP-2a-
DK21); and strain CDC89 (serotype Ia, expressing BP-2a-
CJB110). Bacteria were grown at 37uC in Todd Hewitt Broth
(Difco Laboratories) or in trypticase soy agar supplemented with
5% sheep blood.
Cloning and protein purification
The full-length BP-2a 515 variant and the mutated form of BP-
2a-515 (BP-2a-515K199A/K355A/K463A) were produced as previous-
ly reported [14]. Recombinant proteins were expressed in E. coli
BL21 (DE3) (Novagen) cells as His-tagged fusion proteins and
purified by affinity chromatography and gel filtration.
Generation of mouse monoclonal antibodies
Mouse monoclonal antibodies (mAbs) were generated by Areta
International (Varese, Italy) using standard protocols. Briefly, B-cell
hybridoma clones were isolated from spleen cells of immunized
CD1 mice with the purified recombinant BP-2a-515 protein.
Positive clones were first selected by ELISA and then culture
supernatants were screened for binding to the surface of GBS 515
strain by flow cytometry. Positive primary hybridoma clones were
subjected to single cell cloning and sub-cloning by limiting
dilution. Monoclonality of a clone was accepted only when all
the wells of a microtitre plate with growing cells gave positive
reaction in indirect ELISA after repeated sub-cloning. The
selected mAbs were finally purified by protein G affinity
chromatography. Classes and subclasses of the monoclonal
antibodies were determined by IsoQuick Mouse Monoclonal
Isotyping Kit (Sigma).
Flow cytometry analysis
Flow Cytometry Analysis (FACS) analysis was performed as
described elsewhere [9]. Briefly, mid-exponential phase bacterial
cells were fixed in 0.08% (wt/vol) paraformaldehyde and
incubated for 1 hour at 37uC. Fixed bacteria were then washed
once with PBS, resuspended in Newborn Calf Serum (Sigma) and
incubated for 20 min. at 25uC. The cells were then incubated for
1 hour at 4uC in presence of mAbs diluted 1:200 in dilution buffer
(PBS, 20% Newborn Calf Serum, 0.1% BSA). Cells were washed
in PBS-0.1% BSA and incubated for a further 1 h at 4uC with a
1:100 dilution of R-Phycoerythrin conjugated F(ab)2 goat anti-
mouse IgG (Jackson ImmunoResearch Laboratories; Inc.). After
washing, cells were resuspended in PBS and analyzed with a
FACS CANTO II apparatus (Becton Dickinson, Franklin Lakes,
NJ) using FlowJo Software (Tree Star, Ashland, OR).
Opsonophagocytosis assay
The assay was performed using differentiated HL-60 as
phagocytic cells and live bacteria as target cells. GBS strain 515
was grown to mid-exponential growth phase (A650 nm= 0.3),
harvested by centrifugation, and, after washing in cold saline
solution, was resuspended in HBSS buffer (Invitrogen). Promy-
elocytic HL-60 cells (ATCC, CCL-240) were expanded in RPMI
1640 (Invitrogen) containing 10% Fetal clone I (HyClone) at 37uC
with 5% CO2 and differentiated into granulocyte-like cells to a
density of 46105 cells/ml by the addition of 100 mM N,N
dimethylformamide (DMF, Sigma) to the growth medium. After 4
days, cells were harvested by centrifugation and resuspended in
HBSS buffer. Briefly, the reactions took place in a total volume of
125 ml containing <36106 differentiated HL-60, <1,56105 CFU
of GBS cells, 10% baby rabbit complement (Cedarlane), and
different dilutions of purified mAbs. Immediately before and after
1 h of incubation at 37uC with shaking at 350 rpm, a 25-ml aliquot
was diluted in sterile distilled water and plated onto trypticase soy
agar plates with 5% sheep blood. A set of negative controls
consisted of reactions without phagocytic cells or with heat-
inactivated complement. The amount of opsonophagocytic killing
(log kill) was determined by subtracting the log of the number of
colonies surviving the 1 h assay from the log of the number of
CFU at the zero time point.
Biosensor analyses
Surface plasmon resonance (SPR) analyses were performed
using a Biacore X100 instrument (GE Healthcare). Protein A and
Protein G (Sigma) were immobilized on CM5 biosensors (Biacore)
using standard primary amine coupling (Amine Coupling Kit, GE
Healthcare) in which the carboxymethylated CM5 dextran layers
were activated by mixing equal volumes of 0.4 M N-ethyl-N9-(3-
dimethylaminopropyl)carbodiimide (EDC) and 0.1 M N-hydro-
xysuccinimide (NHS) at a flow rate of 10 mL/min for 7 min
injection. Protein A (250 mg/mL) and Protein G (150 mg/mL) in
10 mM sodium acetate pH 4.5, were immobilized on the activated
biosensors using a contact time of 9 min at 10 mL/min flow rate.
Unreacted NHS-esters were blocked with three injections (4 min
each) of 1.0 M ethanolamine hydrochloride, pH 8.5. The
immobilization procedure allowed obtaining a Protein A and a
Protein G coated biosensors of ,3500 RU and ,1000 RU
respectively. Untreated flow cell 1 was used as reference. PBS
buffer pH 7.2 with 0.005% (v/v) Tween 20 was used as running
buffer for protein immobilization and binding experiments.
To perform single cycle kinetics (SCK), monoclonal antibodies
(ranging from 5 to 15 nM in running buffer) were captured onto
the Protein A and Protein G surfaces, according to their isotype, at
a flow rate of 2 mL/min for 4 min injection.
The analyte BP-2a 515 variant in 2-fold serial dilutions in
running buffer (starting from 500 or 250 nM, five concentrations
in total) was injected over the captured antibody for 2 min at
45 mL/min followed by a 5 or 10 min dissociation. Biosensor
regeneration was performed after each cycle and achieved using
urea 8 M, pH 10.5 (4 min, 10 mL/min). This treatment did not
damage the biosensor surface as shown by equivalent signals of
capturing ligand on different runs. Each kinetic experiment was
preceded by an identical binding-regeneration cycle of buffer as
analyte after mAb capture. This cycle was used as blank and
subtracted from all the active curves to correct background effects.
The association, dissociation and affinity constants (ka e kd and
KD respectively) were determined by a simultaneous fitting of the
kinetic curves with a model of equimolar stoichiometry (1:1) using
the BIAevaluation X100 software version 1.0 (GE Healthcare).
Epitope mapping with monoclonal antibodies
The epitope-mapping approach was based on the method
described by Peter and Tomer [24], which we adapted to the
following two protocols [25,26]:
1) Immunocapturing of peptides from antigen partial
digestion. Peptide mixtures were obtained by digestion of BP-
2a with trypsin, GluC and LysC (independently) in 50 mM
ammonium bicarbonate buffer in a ratio 10:1 at 37uC for 3 h. To
capture the epitope-containing peptide, a 25 ml suspension of
Dyanbeads Pan Mouse IgG (uniform, superparamagnetic polysty-
rene beads of 4.5 mm diameter coated with monoclonal human
antimouse IgG antibodies) was used. The beads were washed twice
with PBS using a magnet and resuspended to the initial volume.
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1 mg of the probe (murine) mAb was added and incubated for
30 min at room temperature, after which the beads were washed
twice with PBS to remove mAb excess. 0.5 ml of Protease Inhibitor
Mix (GE Healthcare) were added prior to the addition of the
peptide mixture to avoid potential degradation of the antibodies.
The sample was incubated for 30 min at room temperature with
gentle tilting and rotation. After incubation the beads were washed
three times with 1 ml PBS, and the bound peptide was then eluted
with 50 ml of 0.2% TFA. The elute fraction was concentrated and
washed with C18 ZipTips (Millipore) and eluted in 3 ml of 50%
ACN and 0.1% TFA. For MALDI-MS analysis, 1 ml of sample
was mixed with the same volume of a solution of alpha-cyano-4-
hydroxy-transcinnamic acid matrix (0.3 mg/ml in
H2O:ACN:TFA at 6:3:1), spotted onto the MALDI target plate
and allowed to air-dry at room temperature. MALDI mass spectra
were recorded in the positive ion mode on an UltrafleXtreme
MALDI TOF/TOF instrument (Bruker Daltonics). Ion acceler-
ation was set to 25 kV. All mass spectra were externally calibrated
using a standard peptide mixture. For MS/MS analysis, the
MASCOT search engine (Matrix Science. London, UK) was used
with the following parameters: one missed cleavage permission,
20 ppm measurement for MS and 0.3 Da for MS/MS tolerance.
Positive identifications were accepted with p values lower than
0.05. In the searches, methionine residues modified to methionine
sulfoxide were allowed.
2) Partial digestion of immunocaptured antigens. To
allow the capture of conformational epitopes, the order of the steps
in the previous protocol was inverted. The intact protein (20 mg)
was added to the beads, allowing binding to the immobilized
mAbs. The protease was then added to the sample in a ratio 50:1,
with incubation at 37uC for 3 h. After proteolysis, the beads were
washed ten times with 1 ml PBS, and the bound peptide was then
eluted as previously described. To avoid the analysis of proteo-
lyzed antibody fragments within the elute fraction, negative
controls were carried out where PBS was used instead of protein
samples.
Sequencing of monoclonal antibodies
Approximately 56106 monoclonal antibody-secreting hybrid-
oma cells were collected. Poly(A)+ RNA was isolated using RNeasy
Mini Kit according to the manufacturer’s instructions (QIAGEN).
cDNA was produced via reverse transcription using ,2 ug of
poly(A)+ RNA template and oligo-(dT)12–18 primer using First
Strand cDNA Synthesis kit (Novagen). The resulting cDNA was
used as a template for PCR amplification using PfuUltra High-
Fidelity DNA Polymerase (Stratagene) and degenerated primers
specific for FvH and FvL gene fragments (Mouse Ig-Primer Set,
Novagen). PCR timing has been set according to the manufac-
turer’s instruction (Mouse Ig-Primer Set, Novagen). Positive PCR
products have been purified using a QIAprep Spin Miniprep Kit
(QIAGEN) and sequenced.
Sequence analysis
A total of 144 S. agalactiae BP-2a sequences were examined both
from GenBank, including previously published sequences [13],
and from complete genome sequences. Codon alignments and
phylogenies were constructed using the coding region for each of
the 22 unique BP-2a gene sequences with MEGA5 [27]. To detect
codons that show signs of adaptive evolution the program HyPhy
[19] was used, as implemented in Datamonkey [28]. The codon-
based maximum likelihood method REL (Random Effects
Likelihood) [29] was used to estimate the dN/dS ratio at every
codon in the alignment. The REL method can also take
recombination into account, provided that prior to the selection
analysis a screening of the sequences for recombination break-
points is performed. The recombination analysis was performed
with GARD [18], using the HKY85 substitution model.
Comparative homology modeling and molecular
docking of mAbs
The corresponding amino acid sequences of monoclonal
antibodies were used to search the Protein Data Bank (PDB) in
order to retrieve suitable templates for modeling. Ten models for
each antibody have been obtained with Moleder 9v8 [30]. The
best models were selected according to the objective function
scoring. The quality of the refined structures obtained was checked
with verify Profile-3D module of Discovery Studio 3.0 (Accelrys).
Molecular docking has been performed with ATTRACT
docking program [31]. The docking protocol of ATTRACT has
already been described in previous publications [16,31]. Briefly,
the antibodies and the target protein (BP-2a 515 variant)
coordinates are translated into a reduced protein presentation
made up to three pseudo atoms per amino acid residue: the
protein backbone is represented by one pseudo atom, small
aminoacid side chains (Ala, Asp, Asn, Cys, Ile, Leu, Pro, Ser, Thr,
Val) are represented by one pseudo atom and larger and more
flexible side chains are represented by two pseudo atoms, to better
describe the shape and dual chemical character of side chains. The
contacts between pseudo atoms are described by different
interaction: Lennard–Jones (LJ)-type potentials (A/r8-B/r6-poten-
tial), repulsive and attractive LJ-parameters describing approxi-
mately the size and physico-chemical character of the side chain
chemical groups [31]. For systematic docking studies, the
antibody, called the ligand protein, was used as probe and placed
at various positions and various orientations on the surface of the
domain D3 of BP-2a 515 crystal structure. We also took into
account the experimental data from Mass analysis, setting a weight
of 1.5 on exposed aminoacid residues identified and on the surface
area (4A) around them. Best docked complexes were selected
according to energy scoring function and were finally energy-
minimized using the Sander program from the Amber8 pack-
age.18. During energy minimization, a Generalized Born (GB)
model was employed to implicitly account for solvation effects as
implemented in Amber8.
Molecular simulations
All molecular dynamics (MD) simulations were performed with
the GROMACS 4.0.5 simulation package [17] using the
AMBER99SB-ILDN force field [32] with explicit water (TIP3P)
[33]. The selected energy minimized complexes served as starting
structure for MD simulations. After stepwise heating of the systems
to 310 K production runs were performed for up to 20 ns with a
time step of 2 fs in the NPT ensemble at 310 K and 1 bar.
Temperature and pressure were controlled by Nose´-Hoover
[34,35] (coupling constant tt = 2.5) and Parrinello-Rahman
[36,37] (tp = 5.0 ps) schemes, respectively. Figures of the molec-
ular structures were generated with VMD [38] and Discovery
Studio 3.0 (Accelrys).
Dot blot immunoassay
Amounts of 5 – 2 – 0.2 mg of purified peptides (Thermo
scientific) were spotted on nitrocellulose membrane (0.45 mm pore
size, Biorad) and left to dry for at least 30 minutes at room
temperature. The spotted membranes were washed three times
with PBST (0.05% Tween 20 in phosphate-buffered saline or PBS
pH 7.4) applying a constant vacuum flow using SNAP i.d. Protein
Detection System (Millipore) and blocked for 1 h at room
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temperature in PBST buffer containing 10% of non-fat-dry milk
(Biorad). The membranes were then probed 1 h at room
temperature with specific anti-BP2a mAb (diluted ,4.5 mg/mL
in PBST/1% non-fat-dry milk) and washed 5 minutes (3X) with
PBST and further incubated in PBST/1% non-fat-dry milk for
1 h containing a dilution of 1:1000 goat anti-mouse horseradish
peroxidase-conjugated secondary antibody (Dako, Glostrup, Den-
mark). Subsequently, the filters were washed 15 minutes (2X) with
PBST and developed by enhanced chemiluminescence (ECL)
detection assay (Pierce ECL Western blotting substrate, Thermo
Fisher Scientific Inc.) following manufacturer’s protocols.
Supporting Information
Figure S1 Amino acid sequences of 22 GBS pilus 2a
backbone proteins (BP-2a) belonging to unique nucleo-
tide sequences and aligned with CLUSTALW. Shaded
residues are those that do not differ from the consensus sequence
(identical in dark gray and similar in light gray). The rest of the
residues are colored according to their physico-chemical proper-
ties. The neutralizing epitope segment is boxed. The sites detected
to evolve under selective pressure with p,0.05 are indicated with
asterisks. The predicted recombination breakpoints in the gene are
shown at the top of the alignment, where each colored bar
represents a proposed recombinant block.
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